Repligen Co. (NASDAQ:RGEN) Stake Lessened by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG cut its stake in Repligen Co. (NASDAQ:RGEN) by 32.3% during the third quarter, HoldingsChannel reports. The fund owned 1,451 shares of the biotechnology company’s stock after selling 693 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Repligen were worth $216,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Toronto Dominion Bank increased its position in Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 89 shares during the period. Diversified Trust Co lifted its stake in Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 106 shares during the period. CWM LLC lifted its stake in Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 114 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Repligen by 24.0% during the third quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 115 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on RGEN shares. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. UBS Group lowered their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Trading Down 4.6 %

RGEN opened at $137.48 on Thursday. The stock has a market capitalization of $7.68 billion, a P/E ratio of 549.92, a P/E/G ratio of 4.24 and a beta of 0.95. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The firm’s fifty day simple moving average is $144.24 and its 200 day simple moving average is $147.63. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 EPS. As a group, research analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.